Login to Your Account



Raptor Falls on Positive Data in Nephropathic Cystinosis

By Jennifer Boggs


Tuesday, July 26, 2011
Raptor Pharmaceuticals Corp.'s RP103, a delayed-release version of cysteamine, hit its primary endpoint in a Phase III study in nephropathic cystinosis, putting the firm in a good position for filing a new drug application (NDA) in the ultra-orphan indication, though that success was not exactly mirrored in the company's stock.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription